Neuren Pharmaceuticals Limited

NURPF

NURPFNeuren Pharmaceuticals Limited US flag

Other OTC

7.95

USD

-2.14

(-21.21%)

0.63EPS

12.62P/E

1.02BMarket Cap

Jan 29Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Neuren Pharmaceuticals Limited

NURPF

(Other OTC)

Recent

price

7.95

P/E

ratio

12.62

div

yld

- -

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 12/02

Stock

S&P500

-27.06

32.18

525.98

31.97

359.54

93.70

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
0.18	0.33	0.22	- -	- -	- -	- -	- -	- -	- -	0.14	- -	- -	- -	0.12	1.83	Revenue per Share
-1.25	0.01	-0.23	-0.12	-0.09	-0.18	-0.11	-0.16	-0.13	0.04	0.03	-0.11	-0.09	-0.07	- -	1.24	Basic EPS, GAAP
-0.74	-0.09	-0.14	- -	-0.05	-0.12	-0.08	-0.15	-0.14	- -	- -	- -	- -	- -	- -	- -	Free Cash Flow per Basic Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Dividend per Share
0.28	0.31	-0.05	0.08	-0.02	0.23	0.26	0.26	0.16	0.26	0.33	0.22	0.32	0.41	0.39	1.66	Book Value per Share
-0.11	0.16	-0.02	0.15	0.05	0.38	0.24	0.17	0.05	0.18	0.25	0.14	0.23	0.33	0.33	1.61	Tangible Book Value per Share
12	15	21	38	59	63	78	84	89	92	99	100	107	118	126	127	Basic Weighted Avg Shares
2	5	5	- -	- -	- -	- -	- -	- -	- -	14	- -	- -	- -	15	232	Sales/Revenue/Turnover
-436.08	-1.05	-103.23	- -	- -	- -	- -	- -	- -	- -	39.07	- -	- -	- -	-11.04	85.89	Operating Margin (%)
1	1	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Depreciation Expense
-15	- -	-5	-5	-5	-11	-8	-13	-12	3	3	-11	-9	-8	- -	157	Net Income, GAAP
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	23.43	Effective Tax Rate (%)
-677.97	1.99	-105.28	- -	- -	- -	- -	- -	- -	- -	22.69	- -	- -	- -	1.26	67.73	Profit Margin (%)
-1	3	- -	6	3	24	19	14	4	15	25	14	24	39	42	204	Working Capital
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	LT Debt
6	7	4	9	6	24	19	14	4	16	25	14	24	39	42	205	Total Equity
- -	- -	- -	- -	- -	- -	- -	- -	- -	-66.01	25.79	- -	- -	- -	-3.97	107.46	Return on Invested Capital (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	17.23	10.81	- -	- -	- -	0.38	120.57	Return on Capital (%)
-298.86	2.48	- -	- -	- -	- -	-47.52	-63.22	-65.58	17.23	10.81	-38.97	-32.35	-18.74	0.38	120.57	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	- -	- -	1,493.66%
Net Income, GAAP	8,457.62%	16,937.11%	85,270.11%
Free Cash Flow	- -	23.46%	110.53%
Total Cash Common Dividend	- -	- -	- -
Total Equity	71.73%	98.49%	393.42%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Similar Companies: Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
BELLUS Health Inc. (BLU.TO)
Stemcell Holdings, Inc. (STMM)
Aeglea BioTherapeutics, Inc. (AGLE)
Cantargia AB (publ) (CANTA.ST)
La Jolla Pharmaceutical Company (LJPC)
Business: Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
0.18	0.33	0.22	- -	- -	- -	- -	- -	- -	- -	0.14	- -	- -	- -	0.12	1.83	Revenue per Share
-1.25	0.01	-0.23	-0.12	-0.09	-0.18	-0.11	-0.16	-0.13	0.04	0.03	-0.11	-0.09	-0.07	- -	1.24	Basic EPS, GAAP
-0.74	-0.09	-0.14	- -	-0.05	-0.12	-0.08	-0.15	-0.14	- -	- -	- -	- -	- -	- -	- -	Free Cash Flow per Basic Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Dividend per Share
0.28	0.31	-0.05	0.08	-0.02	0.23	0.26	0.26	0.16	0.26	0.33	0.22	0.32	0.41	0.39	1.66	Book Value per Share
-0.11	0.16	-0.02	0.15	0.05	0.38	0.24	0.17	0.05	0.18	0.25	0.14	0.23	0.33	0.33	1.61	Tangible Book Value per Share
12	15	21	38	59	63	78	84	89	92	99	100	107	118	126	127	Basic Weighted Avg Shares
2	5	5	- -	- -	- -	- -	- -	- -	- -	14	- -	- -	- -	15	232	Sales/Revenue/Turnover
-436.08	-1.05	-103.23	- -	- -	- -	- -	- -	- -	- -	39.07	- -	- -	- -	-11.04	85.89	Operating Margin (%)
1	1	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Depreciation Expense
-15	- -	-5	-5	-5	-11	-8	-13	-12	3	3	-11	-9	-8	- -	157	Net Income, GAAP
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	23.43	Effective Tax Rate (%)
-677.97	1.99	-105.28	- -	- -	- -	- -	- -	- -	- -	22.69	- -	- -	- -	1.26	67.73	Profit Margin (%)
-1	3	- -	6	3	24	19	14	4	15	25	14	24	39	42	204	Working Capital
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	LT Debt
6	7	4	9	6	24	19	14	4	16	25	14	24	39	42	205	Total Equity
- -	- -	- -	- -	- -	- -	- -	- -	- -	-66.01	25.79	- -	- -	- -	-3.97	107.46	Return on Invested Capital (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	17.23	10.81	- -	- -	- -	0.38	120.57	Return on Capital (%)
-298.86	2.48	- -	- -	- -	- -	-47.52	-63.22	-65.58	17.23	10.81	-38.97	-32.35	-18.74	0.38	120.57	Return on Common Equity (%)

Neuren Pharmaceuticals Limited

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Growth Rates

(avg. rate of change)

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year